Inflammatory Myositis - Initial Workup

Key Points

• Objective proximal weakness is more characteristic than pain alone.
• Assess dysphagia, respiratory muscle weakness, ILD, and myocarditis because they can be life-threatening.
• CK can be normal in some inflammatory myopathy phenotypes.
• Myositis-specific antibodies help define subtype, lung risk, and malignancy associations.
• Glucocorticoids usually require an early steroid-sparing immunosuppressant for sustained control.
• IVIG is valuable in severe dermatomyositis and dysphagia among selected patients.
• Adult-onset myositis requires risk-stratified malignancy screening.
• Exercise and rehabilitation are beneficial once acute disease is stabilized.

Algorithm

1. Confirm true objective weakness and map proximal/distal, neck, bulbar and respiratory involvement.
2. Obtain CK, aldolase, AST/ALT, LDH, CBC/CMP, TSH and myositis/autoimmune serologies.
3. Assess swallowing and respiration; obtain PFTs/HRCT for suspected ILD and ECG/troponin/echo for cardiac concern.
4. Use MRI/EMG and muscle or skin biopsy when needed to establish subtype or exclude mimics.
5. Start glucocorticoid treatment for active disease and add phenotype-appropriate steroid-sparing therapy.
6. Use IVIG or advanced immunosuppression for severe dysphagia, refractory disease or selected organ-threatening presentations.
7. Perform IMACS risk-stratified cancer screening in adult-onset disease.
8. Begin rehabilitation, sun protection and long-term monitoring of strength, CK, lung function and medication toxicity.

Clinical Synopsis & Reasoning

Inflammatory myopathies include dermatomyositis, immune-mediated necrotizing myopathy, antisynthetase syndrome, polymyositis-like syndromes, and overlap myositis. The classic complaint is progressive proximal weakness over weeks to months: difficulty rising from a chair, climbing stairs, lifting objects overhead, or combing hair. Myalgia may occur but is not required. Dermatomyositis clues include heliotrope rash, Gottron papules/sign, shawl or V-sign photosensitivity, scalp inflammation, and nailfold changes. Antisynthetase syndrome can feature interstitial lung disease, inflammatory arthritis, Raynaud phenomenon, fever, and mechanic’s hands.

CK is often markedly elevated but can be normal or only mildly elevated in some dermatomyositis or chronic disease. Aldolase, AST/ALT, LDH, myositis-specific antibodies, ANA and associated serologies refine the phenotype. MRI can identify muscle edema and guide biopsy; EMG can support an irritable myopathy. Muscle or skin biopsy is useful when diagnosis/subtype remains uncertain. Important mimics include statin-associated toxic or immune-mediated myopathy, hypothyroidism, muscular dystrophy, neurologic disease, steroid myopathy, infection, electrolyte disorders, rhabdomyolysis, and inclusion-body myositis. Assess swallowing, respiratory strength, oxygenation, ECG/troponin when cardiac symptoms exist, and chest imaging/PFTs for interstitial lung disease.

Treatment Strategy & Disposition

Organ threat determines urgency. Severe dysphagia, respiratory muscle weakness, rapidly progressive interstitial lung disease, myocarditis, or profound weakness may require hospitalization and high-dose IV or oral glucocorticoids with early additional immunosuppression. For typical active myositis, start glucocorticoid therapy and introduce a steroid-sparing agent such as methotrexate, azathioprine, mycophenolate, tacrolimus, or another agent selected for phenotype and lung involvement. IVIG has an important role in severe dermatomyositis, dysphagia, and selected refractory disease. Rituximab and other advanced therapies are used in refractory or organ-threatening subsets.

Cancer screening is a core part of adult-onset inflammatory myopathy. The 2023 IMACS guideline stratifies malignancy risk by subtype, autoantibodies, age, and clinical features, with enhanced screening for moderate/high-risk patients around the period of myositis onset. Dermatomyositis, anti-TIF1-gamma positivity, anti-NXP2 in certain contexts, older age, dysphagia, cutaneous necrosis, and refractory disease can increase concern. Continue ordinary age/sex-appropriate screening plus risk-stratified additional testing. Physical therapy should begin once acute muscle injury is controlled; prolonged inactivity worsens deconditioning. Sun protection is important in dermatomyositis.

Epidemiology / Risk Factors

• Inflammatory myopathies are rare and heterogeneous; accurate subtype classification improves management.
• Adult dermatomyositis carries a clinically important malignancy association concentrated around disease onset.
• Interstitial lung disease is a major source of morbidity in antisynthetase and MDA5-associated disease.
• Women are affected more often in several subtypes, but immune-mediated necrotizing myopathy and inclusion-body myositis have different demographics.

Investigations

Red Flags

Pharmacology

Prognosis / Complications

• Many patients regain substantial strength with early therapy, but recovery may take months and chronic damage/deconditioning can persist.
• Rapidly progressive ILD, severe dysphagia, myocarditis and malignancy-associated disease worsen prognosis.
• Relapses can occur during steroid taper if steroid-sparing therapy is insufficient.
• Cancer risk is highest near myositis onset and requires structured surveillance according to risk category.

Patient Education / Counseling

• Report new shortness of breath, dry cough, choking, nasal regurgitation, chest pain, palpitations, or rapidly worsening weakness urgently.
• Explain that CK is only one disease marker and strength/function matter equally.
• Use sun protection and dermatologic therapy for dermatomyositis skin disease.
• Participate in supervised exercise/physical therapy rather than prolonged bed rest once medically stable.
• Complete the recommended cancer-screening program even when the muscle symptoms improve.

Notes

The diagnostic label “polymyositis” should be used cautiously because modern antibody and pathology classification reassigns many historical cases to immune-mediated necrotizing myopathy, antisynthetase syndrome, overlap myositis, or inclusion-body myositis. Subtyping is clinically important because treatment response, lung risk, and cancer association differ.

Cancer screening should follow the international IMACS risk framework rather than indiscriminate whole-body testing forever. The highest-yield period is around adult disease onset, and intensity depends on subtype, autoantibodies and clinical risk factors. Standard population screening still continues alongside any enhanced program.

References

1. International Guideline for IIM-Associated Cancer Screening, IMACS 2023 — Link